AGTC - Applied Genetic on the rise ahead of data read for Achromatopsia trial

kamisoka/iStock via Getty Images Applied Genetic Technologies (AGTC) has added ~14.2% in the post-market after announcing that the company will present 12-month data from its Phase 1/2 Achromatopsia trials tomorrow. The results will focus on adult patients and low-dose pediatric patients. The management has scheduled a conference call and webcast on June 24 at 8:00 AM EST “to review the ACHM CNGB3 and CNGA3 data and provide an update on the trials,” Applied Genetic said in the statement referring to achromatopsia studies. ACHM an inherited retinal disease results in sharply lower visual acuity, extreme light sensitivity causing day blindness, and complete loss of color discrimination. In January, Applied Genetic climbed in reaction to preliminary results based on a patient-by-patient analysis of data from ACHMB3 and ACHMA3 clinical trials.

For further details see:

Applied Genetic on the rise ahead of data read for Achromatopsia trial